Syschem (India) Limited, a leading pharmaceutical manufacturing company, is pleased to announce the successful commencement of commercial production at its new production unit as well as the expanded capacity of its existing unit, effective January 5, 2026. This milestone follows the successful completion of trial production and marks a significant step forward in the Company’s growth and capacity enhancement strategy.
The Company has commenced commercial operations at its new production unit named “Ganga”, located at Village Bargodam, Tehsil Kalka, District Panchkula, Haryana. This state-of-the-art facility has been established to manufacture key antibiotic products, including Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium.
The Ganga unit has an installed capacity of 600 metric tonnes per annum, significantly strengthening Syschem (India) Limited’s manufacturing capabilities. Commercial production officially began on January 5, 2026, following successful trial runs that validated the unit’s operational readiness, quality standards, and compliance with regulatory requirements.
The commencement of this new unit is expected to substantially enhance the Company’s overall production capacity, improve operational efficiency, and support the Company in meeting increasing domestic and international market demand. The Company confirms that there has been no material deviation from the original project plan as previously disclosed.
In addition to the new unit, Syschem (India) Limited has also commenced commercial production from the expanded capacity of its existing manufacturing unit, “SARU”, located at Village Bargodam, Tehsil Kalka, District Panchkula, Haryana. The SARU unit expansion is focused on the manufacturing of Amoxicillin, one of the most widely used antibiotic products globally. With this expansion, the unit now has an installed capacity of 1,200 metric tonnes per annum. Commercial production from the expanded facility also began on January 5, 2026, aligning with the Company’s strategic capacity augmentation plans.
The expansion is expected to enhance production volumes, improve economies of scale, and enable Syschem (India) Limited to better serve its customers amid growing market demand. Similar to the new unit, the Company confirms that the expansion has been executed without any material deviation from the previously disclosed plans.
The commissioning of both the Ganga unit and the expanded SARU unit represents a major operational milestone for Syschem (India) Limited. Together, these developments are expected to strengthen the Company’s manufacturing infrastructure, improve operational efficiencies, and reinforce its position in the pharmaceutical active ingredients segment.
Syschem (India) Limited remains committed to sustainable growth, operational excellence, and delivering high-quality pharmaceutical products to its customers. The Company will continue to focus on capacity expansion, technological advancement, and compliance with global quality standards as part of its long-term strategic vision.
Syschem (India) Limited is engaged in the manufacturing of pharmaceutical active ingredients and intermediates, catering to domestic and international markets with a strong emphasis on quality, reliability, and innovation.
